• Life expectancy in glioblastoma patients who had undergone stereotactic biopsy: a retrospective single-center study
• THOC2 expression and its impact on 5-fluorouracil resistance in glioblastoma multiforme
• Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
• SRSF1 induces glioma progression and has a potential diagnostic application in grading primary glioma
• Glioblastoma with a primitive neuronal component: A case report
• Management of glioblastoma multiform (GBM) during the SARS-COV-2 pandemic: A review of the literature
• A cellular ground truth to develop MRI signatures in glioma models by correlative light sheet microscopy and atlas-based co-registration
• NCAPG promotes the progression of glioblastoma by facilitating PARP1-mediated E2F1 transactivation

Advances in glioblastoma diagnosis and glioblastoma surgery mean that radical resections can be performed even in eloquent brain areas. However, patients not indicated for resection will experience a major reduction in life expectancy. Patients who underwent stereotactic biopsy and received some form of oncological treatment experienced slightly increased overall survival relative to patients with a natural disease course. Patients with favorable clinical factors reacted better to treatment ¹⁾

Glioblastoma overall survival.

Glioblastoma patients who were readmitted within 30 days had significantly shorter survival than nonreadmitted patients. Future studies that attempt to decrease readmissions and evaluate the impact of reducing readmissions on patient outcomes are needed ²⁾.

Despite advances in treatment, the median patient survival is 12 to 15 months ³⁾.

Glioblastoma progression.